159 filings
Page 3 of 8
8-K
yw65 yvq6
27 Aug 07
Oscient Pharmaceuticals Names Aaron D. Berg Vice President of Marketing
12:00am
8-K
helj7rfxatxl7fl4fjcb
17 Aug 07
Oscient Pharmaceuticals Receives Nasdaq Staff Letter
12:00am
8-K
ppiqhzl5 gm1i
3 Aug 07
Oscient Pharmaceuticals Reports Financial Results for Second Quarter 2007
12:00am
8-K
czf5aanklfmq9f1jph7d
13 Jul 07
Oscient Pharmaceuticals Provides Preliminary Revenue Results for the Second Quarter of 2007
12:00am
8-K
7hq9lecpw
13 Jun 07
Other Events
12:00am
8-K
s436a3olqa2zyferd0
4 May 07
Oscient Pharmaceuticals Reports Financial Results for First Quarter 2007
12:00am
8-K
g0fajgv8
11 Apr 07
Oscient Pharmaceuticals Provides Preliminary Revenue Results for the First Quarter of 2007
12:00am
8-K
h6ynq2wmbsscmv
5 Mar 07
Abbott Canada Launches Oscient Pharmaceuticals’ FACTIVE Tablets in Canada
12:00am
8-K
9buziwza7l6bq148jf
28 Feb 07
Oscient Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2006
12:00am
8-K
ng391bnnrjrvmv
23 Feb 07
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
12:00am
8-K
vzioha1
9 Jan 07
Oscient Pharmaceuticals Provides Preliminary Revenue Results for Fourth Quarter and Fiscal Year 2006
12:00am
8-K
0cmmrajbrjj
4 Jan 07
Entry into a Material Definitive Agreement
12:00am
8-K
oq0ri2
29 Dec 06
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
12:00am
8-K
voe4r 07r0uva
11 Dec 06
Departure of Directors or Principal Officers
12:00am
8-K
gbi8vr
8 Dec 06
Other Events
12:00am
8-K
5iksb
28 Nov 06
FDA Accepts as “Complete Response” Oscient Pharmaceuticals’ Submission Following
12:00am
8-K
akuewd3hfca8fs5d
22 Nov 06
Departure of Directors or Principal Officers
12:00am
8-K
ntegkz4teyodzrxcjgrc
15 Nov 06
Material Modifications to Rights of Security Holders
12:00am
8-K
61y78amdc gryg1u4
14 Nov 06
Regulation FD Disclosure
12:00am
8-K
u2mu6ul19przlta8f3g
9 Nov 06
Oscient Pharmaceuticals Reports Financial Results for Third Quarter of 2006
12:00am